000069473 001__ 69473
000069473 005__ 20191212100659.0
000069473 0247_ $$2doi$$a10.1186/s12885-018-4004-7
000069473 0248_ $$2sideral$$a104609
000069473 037__ $$aART-2018-104609
000069473 041__ $$aeng
000069473 100__ $$aArriola, E.
000069473 245__ $$aClinical management and outcome of patients with advanced NSCLC carrying EGFR mutations in Spain
000069473 260__ $$c2018
000069473 5060_ $$aAccess copy available to the general public$$fUnrestricted
000069473 5203_ $$aBackground: Although the benefit of first-line epidermal growth factor receptor (EGFR) tyrosine-kinase inhibitors (TKIs) over chemotherapy has been demonstrated in several clinical trials, data from clinical practice is lacking and the optimal EGFR TKI to be used remains unclear. This study aims to assess the real-life diagnostic and clinical management and outcome of patients with advanced non-small-cell lung cancer (NSCLC) carrying EGFR mutations in Spain. Methods: All consecutive patients recently diagnosed with advanced or metastatic NSCLC from April 2010 to December 2011 in 18 Spanish hospitals and carrying EGFR mutations were retrospectively evaluated. Results: Between March and November 2013, a total of 187 patients were enrolled (98.3% Caucasian, 61.9% female, 54.9% never-smokers, 89.0% adenocarcinoma). Mutation testing was mainly performed on biopsy tumour tissue specimens (69.0%) using a qPCR-based test (90%) (47.0% Therascreen EGFR PCR Kit). Common sensitising mutations were detected in 79.8% of patients: 57.1% had exon 19 deletions and 22.6% exon 21 L858R point mutations. The vast majority of patients received first-line therapy (n=168; 92.8%). EGFR TKIs were the most commonly used first-line treatment (81.5%), while chemotherapy was more frequently administered as a second- and third-line option (51.9% and 56.0%, respectively). Of 141 patients who experienced disease progression, 79 (56.0%) received second-line treatment. After disease progression on first-line TKIs (n=112), 33.9% received chemotherapy, 8.9% chemotherapy and a TKI, and 9.8% continued TKI therapy. Most patients received first-line gefitinib (83.0%), while erlotinib was more frequently used in the second-line setting (83.0%). Progression-free survival (PFS) and overall survival (OS) in patients harbouring common mutations were 11.1months and 20.1months respectively (exon 19 deletions: 12.4 and 21.4months; L858R: 8.3 and 14.5months), and 3.9months and 11.1months respectively for those with rare mutations. Conclusion: EGFR TKIs (gefitinib and erlotinib) are used as the preferred first-line treatment while chemotherapy is more frequently administered as a second- and third-line option in routine clinical practice in Spain. In addition, efficacy data obtained in the real-life setting seem to concur with data from EGFR TKI phase III pivotal studies in NSCLC.
000069473 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttp://creativecommons.org/licenses/by/3.0/es/
000069473 590__ $$a2.933$$b2018
000069473 591__ $$aONCOLOGY$$b121 / 229 = 0.528$$c2018$$dQ3$$eT2
000069473 592__ $$a1.336$$b2018
000069473 593__ $$aCancer Research$$c2018$$dQ1
000069473 593__ $$aOncology$$c2018$$dQ1
000069473 593__ $$aGenetics$$c2018$$dQ1
000069473 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000069473 700__ $$aGarcía Gómez, R.
000069473 700__ $$aDiz, P.
000069473 700__ $$aMajem, M.
000069473 700__ $$aMartínez Aguillo, M.
000069473 700__ $$aValdivia, J.
000069473 700__ $$aParedes, A.
000069473 700__ $$aSánchez-Torres, J.M.
000069473 700__ $$aPeralta Muñoz, S.
000069473 700__ $$aBarneto, I.
000069473 700__ $$aGutierrez, V.
000069473 700__ $$aAndrade Santiago, J.M.
000069473 700__ $$aAparisi, F.
000069473 700__ $$aIsla, D.
000069473 700__ $$aPonce, S.
000069473 700__ $$aVicente Baz, D.
000069473 700__ $$0(orcid)0000-0002-3662-7660$$aArtal, A.$$uUniversidad de Zaragoza
000069473 700__ $$aAmador, M.
000069473 700__ $$aProvencio, M.
000069473 7102_ $$11007$$2610$$aUniversidad de Zaragoza$$bDpto. Medicina, Psiqu. y Derm.$$cArea Medicina
000069473 773__ $$g18, 1 (2018), 106 [10 pp]$$pBMC CANCER$$tBMC CANCER$$x1471-2407
000069473 8564_ $$s682784$$uhttps://zaguan.unizar.es/record/69473/files/texto_completo.pdf$$yVersión publicada
000069473 8564_ $$s90773$$uhttps://zaguan.unizar.es/record/69473/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000069473 909CO $$ooai:zaguan.unizar.es:69473$$particulos$$pdriver
000069473 951__ $$a2019-12-12-10:03:25
000069473 980__ $$aARTICLE